ClinicalTrials.gg
RecruitingNCT07507890Mini-BUpdated Apr 2, 2026

Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer

An interventional study of Endoscopic Nipple-Sparing Mastectomy (E-NSM) in Breast Cancer - Ductal Carcinoma in Situ (DCIS) and Breast Cancer, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Jun 2025, registered Mar 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 887 studies in Breast Neoplasms with a site in Italy — 231 open to participants now, 350 under way, 86 of them phase 3. Breast Neoplasms · Italy.

Planned enrollment
673rd of 687
10 · median 208
Started
2025
with 61 others
No phase
161 of 887
53 open now
Primary completion
2026-06
later than 143 of 349 live
Registered
862nd of 887
by date

Among the 887 studies in Breast Neoplasms with a site in Italy, this one is the 673rd largest by planned enrollment of the 687 interventional ones that give a count, is one of 62 that started in 2025, is one of 161 with no phase, reaches primary completion later than 143 of the 349 other live ones, and was the 862nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

231 of the 887 studies in Breast Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

226 more — sign in →

All 231 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 887 studies in Breast Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

This single-center prospective study will evaluate the feasibility and safety of endoscopic nipple-sparing mastectomy (E-NSM) performed through a single axillary incision in selected women with breast cancer undergoing direct-to-implant breast reconstruction. The study will assess procedural feasibility, completeness of resection, short-term postoperative complications, and patient-reported outcomes

Read the detailed description

MINI-B is a single-institution prospective study conducted at the Breast Surgery Unit of Candiolo Cancer Center, Istituto di Candiolo FPO-IRCCS, Torino, Italy. The study will enroll 10 consecutive adult female patients with early-stage invasive breast cancer or ductal carcinoma in situ who are candidates for nipple-sparing mastectomy with direct-to-implant reconstruction and are suitable for a minimally invasive approach. The investigated procedure is endoscopic nipple-sparing mastectomy performed through a single hidden axillary incision using a standardized technique modeled on the robotic nipple-sparing mastectomy procedure already in use at the institution. The study will evaluate feasibility through technical and perioperative parameters, assess resection completeness by margin status, record postoperative complications over 3 months, and collect patient-reported quality-of-life data using BREAST-Q/EORTC questionnaires.

03

Conditions studied

  • Breast Cancer - Ductal Carcinoma in Situ (DCIS)
  • Breast Cancer

Browse trials for

Keywords

  • Breast
  • Endoscopic Nipple-Sparing
  • Mastectomy
  • E-NSM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 years or older.
  • Diagnosis of early-stage invasive breast cancer or ductal carcinoma in situ, including multifocal or multicentric disease.
  • Candidate for nipple-sparing mastectomy with immediate direct-to-implant reconstruction.
  • Small- to medium-sized breasts with ptosis grade 2 or less.
  • Written provided.

Exclusion criteria

Exclusion Criteria:

  • Preoperative evidence of skin involvement, nipple-areola complex involvement, lymph-node , inflammatory breast cancer, Paget's disease, mesenchymal breast tumors, or recurrent breast cancer.
  • Previous ipsilateral breast surgery.
  • Previous thoracic radiation therapy.
  • Heavy smoking (>20 cigarettes/day), uncontrolled diabetes mellitus, or >30.
  • 3 or higher.
  • Ongoing pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single-Arm Endoscopic Nipple-Sparing Mastectomy

    Eligible participants with breast cancer or ductal carcinoma in situ will undergo endoscopic nipple-sparing mastectomy through a single axillary incision, with immediate direct-to-implant breast reconstruction

    Procedure: Endoscopic Nipple-Sparing Mastectomy (E-NSM)

Interventions

  • ProcedureEndoscopic Nipple-Sparing Mastectomy (E-NSM)

    Endoscopic nipple-sparing mastectomy performed through a single extra-mammary axillary incision using a standardized minimally invasive surgical technique; immediate direct-to-implant reconstruction will be performed according to institutional practice.

06

What researchers measure

Primary outcomes

  1. Successful completion of endoscopic nipple-sparing mastectomy without conversion to open surgery

    Number of participants in whom the planned endoscopic nipple-sparing mastectomy through a single axillary incision is completed without conversion to an open technique

    Time frame: During the index surgical procedure

  2. Total operative time

    Operative time for the endoscopic nipple-sparing mastectomy procedure, measured from skin incision to completion of wound closure

    Time frame: During the index surgical procedure

  3. Negative surgical margin rate

    Number of participants with tumor-free surgical margins on final pathological examination of the mastectomy specimen

    Time frame: From surgery to final pathology assessment, up to 30 days after surgery

Secondary outcomes

  1. Length of postoperative hospitalization

    Postoperative length of hospital stay, measured as the number of days from the date of surgery to the date of hospital discharge.

    Time frame: From the date of surgery to hospital discharge during the index hospitalization, assessed up to 30 days

  2. Participants with at least 1 postoperative complication

    Number of participants with at least 1 postoperative complication, defined as nipple-areola complex necrosis, mastectomy skin flap necrosis, surgical-site infection, postoperative bleeding/hematoma, seroma requiring aspiration or drainage, or wound dehiscence.

    Time frame: From the date of surgery to 3 months after surgery

  3. Participants with at least 1 major postoperative complication

    Number of participants with at least 1 major postoperative complication, defined as any postoperative complication requiring reoperation or rehospitalization, or resulting in implant loss

    Time frame: From the date of surgery to 3 months after surgery

  4. BREAST-Q Satisfaction With Breasts score

    Patient-reported satisfaction with breasts assessed using the BREAST-Q Reconstruction Module, Satisfaction With Breasts scale. Scores range from 0 to 100, with higher scores indicating greater satisfaction and a better outcome

    Time frame: Baseline (preoperative assessment) and 3 months after surgery

  5. BREAST-Q Reconstruction Module Psychosocial Well-Being score

    Patient-reported psychosocial well-being assessed using the BREAST-Q Reconstruction Module, Psychosocial Well-Being scale. Scores range from 0 to 100, with higher scores indicating better psychosocial well-being

    Time frame: Baseline (preoperative assessment) and 3 months after surgery

  6. BREAST-Q Reconstruction Module Physical Well-Being: Chest score

    Patient-reported physical well-being of the chest assessed using the BREAST-Q Reconstruction Module, Physical Well-Being: Chest scale. Scores range from 0 to 100, with higher scores indicating better physical well-being

    Time frame: Baseline (preoperative assessment) and 3 months after surgery

  7. BREAST-Q Reconstruction Module Sexual Well-Being score

    Patient-reported sexual well-being assessed using the BREAST-Q Reconstruction Module, Sexual Well-Being scale. Scores range from 0 to 100, with higher scores indicating better sexual well-being

    Time frame: Baseline (preoperative assessment) and 3 months after surgery

07

Study locations

1 of 1 sites recruiting
  • Breast Unit
    Candiolo, Turin 10060, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Apr 2, 2026
StartActual
Jun 11, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507890
Lead sponsor
Fondazione del Piemonte per l'Oncologia
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Jun 11, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Antonio Toesca, MD
Contact
antonio.toesca@ircc.it
0119933628 ext. +39
Giada Pozzi, MD
Contact
giada.pozzi@ircc.it
0119933676 ext. +39

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion